Measuring cerebral enzymatic activity, brain pH and extracranial muscle metabolism with hyperpolarized 13C-pyruvate.
Published version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
Hyperpolarized carbon-13 (13C) magnetic resonance imaging (MRI) has shown promise for non-invasive assessment of the cerebral metabolism of [1-13C]pyruvate in both healthy volunteers and patients. The exchange of pyruvate to lactate catalysed by lactate dehydrogenase (LDH) and that of pyruvate flux to bicarbonate through pyruvate dehydrogenase (PDH) are the most widely studied reactions in vivo. Here we show the potential of the technique to probe additional enzymatic activity within the brain. Approximately 50 s after intravenous injection of hyperpolarized pyruvate, high-flip-angle pulses were used to detect cerebral 13C-labelled carbon dioxide (13CO2), in addition to the 13C-bicarbonate (H13CO3 -) subsequently formed by carbonic anhydrase (CA). Brain pH measurements, which were weighted towards the extracellular compartment, were calculated from the ratio of H13CO3 - to 13CO2 in seven volunteers using the Henderson-Hasselbalch equation, demonstrating an average pH ± SD of 7.40 ± 0.02, with inter-observer reproducibility of 0.04. In addition, hyperpolarized [1-13C]aspartate was also detected, demonstrating irreversible pyruvate carboxylation to oxaloacetate by pyruvate carboxylase (PC) and subsequent transamination by aspartate aminotransferase (AST), with the average flux being on average 11% ± 3% of that through PDH. A hyperpolarized [1-13C]alanine signal was also detected, but this was localized to extracranial muscle tissue in keeping with skeletal alanine aminotransferase (ALT) activity. The results demonstrate the potential of hyperpolarized 13C-MRI to assess cerebral and extracerebral [1-13C]pyruvate metabolism in addition to LDH and PDH activity. Non-invasive measurements of brain pH could be particularly important in assessing cerebral pathology given the wide range of disease processes that alter acid-base balance.
Description
Publication status: Published
Funder: NIHR Cambridge Biomedical Research Centre; doi: http://dx.doi.org/10.13039/501100018956
Funder: National Institute for Health and Care Research; doi: http://dx.doi.org/10.13039/501100000272
Funder: Cancer Research UK; doi: http://dx.doi.org/10.13039/501100000289
Funder: Lundbeck Foundation; doi: http://dx.doi.org/10.13039/501100003554
Funder: Multiple Sclerosis Society; doi: http://dx.doi.org/10.13039/501100000381
Funder: Cambridge Biomedical Research Centre; doi: http://dx.doi.org/10.13039/501100018956
Funder: CRUK Cambridge Centre; doi: http://dx.doi.org/10.13039/501100014679
Funder: Cambridge Experimental Cancer Medicine Centre; doi: http://dx.doi.org/10.13039/501100018956
Funder: Evelyn Trust; doi: http://dx.doi.org/10.13039/501100004282
Funder: Addenbrooke's Charitable Trust; doi: http://dx.doi.org/10.13039/501100002927
Funder: Canadian Institute for Advanced Research (CIFAR); doi: http://dx.doi.org/10.13039/100007631
Funder: Gates Cambridge Trust; doi: http://dx.doi.org/10.13039/501100005370
Funder: NIHR/Wellcome Trust Cambridge Clinical Research Facility
Journal Title
Conference Name
Journal ISSN
1099-1492
Volume Title
Publisher
Publisher DOI
Rights and licensing
Sponsorship
Cancer Research UK (C12912/A27150)
National Institute for Health and Care Research (IS-BRC-1215-20014)
Cancer Research UK (C19212/A29082)
Multiple Sclerosis Society (35)
Lundbeck Foundation (via Aarhus University) (L. Hanberg/J.Gaarde Kristensen)

